7596-60-3

Basic information

• Product Name: 6-Chloro-9-(beta-D-arabinofuranosyl)purine
• Synonyms: 6-Chloro-9-(beta-D-arabinofuranosyl)purine;9-(β-D-Arabinofuranosyl)-6-chloropurine;9-b-D-arabinofuranosyl-6-chloro-9H-Purine
• CAS NO: 7596-60-3
• Molecular Formula: C₁₀H₁₁ClN₄O₄
• Molecular Weight: 286.67174
• Mol File: 7596-60-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 2.03
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-Chloro-9-(beta-D-arabinofuranosyl)purine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-9-(beta-D-arabinofuranosyl)purine(7596-60-3)
• EPA Substance Registry System: 6-Chloro-9-(beta-D-arabinofuranosyl)purine(7596-60-3)

Safety Data

• Hazardous Substances Data: 7596-60-3(Hazardous Substances Data)

Usage

General Description

6-Chloro-9-(beta-D-arabinofuranosyl)purine is a chemical compound that belongs to the class of purine analogs. It is a synthetic nucleoside analogue with antiviral and antineoplastic properties. It works by inhibiting the synthesis of viral DNA, RNA, and proteins, making it effective in the treatment of viral infections such as herpes simplex and varicella-zoster virus infections. Additionally, it has also been investigated for its potential in the treatment of various cancers, including leukemia and lymphoma. 6-Chloro-9-(beta-D-arabinofuranosyl)purine is a promising candidate for the development of new antiviral and anticancer drugs due to its potent biological activities.

Upstream product

• 38819-10-2 9-β-D-arabinofuranosylguanine 
• 87-42-3 6-chloropurine 

Downstream Products

• 574-25-4 6-thio-inosine 

Relevant articles and documents

Enzymatic Synthesis of Therapeutic Nucleosides using a Highly Versatile Purine Nucleoside 2’-DeoxyribosylTransferase from Trypanosoma brucei

The use of enzymes for the synthesis of nucleoside analogues offers several advantages over multistep chemical methods, including chemo-, regio- and stereoselectivity as well as milder reaction conditions. Herein, the production, characterization and utilization of a purine nucleoside 2’-deoxyribosyltransferase (PDT) from Trypanosoma brucei are reported. TbPDT is a dimer which displays not only excellent activity and stability over a broad range of temperatures (50–70 °C), pH (4–7) and ionic strength (0–500 mM NaCl) but also an unusual high stability under alkaline conditions (pH 8–10). TbPDT is shown to be proficient in the biosynthesis of numerous therapeutic nucleosides, including didanosine, vidarabine, cladribine, fludarabine and nelarabine. The structure-guided replacement of Val11 with either Ala or Ser resulted in variants with 2.8-fold greater activity. TbPDT was also covalently immobilized on glutaraldehyde-activated magnetic microspheres. MTbPDT3 was selected as the best derivative (4200 IU/g, activity recovery of 22 %), and could be easily recaptured and recycled for >25 reactions with negligible loss of activity. Finally, MTbPDT3 was successfully employed in the expedient synthesis of several nucleoside analogues. Taken together, our results support the notion that TbPDT has good potential as an industrial biocatalyst for the synthesis of a wide range of therapeutic nucleosides through an efficient and environmentally friendly methodology.